Current and future role of biomarkers in Crohn's disease risk assessment and treatment

Tamboli, Cyrus; Doman, David B.; Patel, Amar D.

doi:10.2147/ceg.s18187

Cited by 14 publications

(8 citation statements)

References 123 publications

(191 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IBS and IBD can exhibit overlapping clinical symptoms making diagnosis difficult without invasive procedures [4,12,34]. Therapy and medication for IBS and IBD are vastly different and incorrect diagnosis and treatment plans have significant consequences.…”

Section: Discussionmentioning

confidence: 99%

“…In patients with indeterminate colitis, those with one or more positive antibodies, including ANCA , ASCA , I2 (antibody to Pseudomonas fluorescens ), and Omp-C, have significantly higher post-operative complications [11]. Other inflammatory biomarkers such as C-reactive protein, fecal calprotectin, and fecal lactoferrin differentiate IBD from other gastrointestinal disorders such as IBS [5], but tests do not differentiate among various types of inflammatory colitides [12]. …”

Section: Introductionmentioning

confidence: 99%

“…A general view is that different profiles of biomarkers could provide useful information to guide clinical decision-making; from diagnosis to choice of optimal therapies and in some cases these biomarker profiles are being implemented in clinical practice [3,12-24]. Searches for optimal biomarker profiles can be achieved using clustering methods e.g ., heirarchical clustering, K-means clustering, which depend upon the general ability to find common features across a sample population or forms of linear discriminate analysis, which depend upon the ability to find linear combinations of features that have the ability to separate two or more classes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Using gene expression data to identify certain gastro-intestinal diseases

Crooke

Tossberg²,

Horst

et al. 2012

J Clin Bioinformatics

View full text Add to dashboard Cite

BackgroundInflammatory bowel diseases, ulcerative colitis and Crohn’s disease are considered to be of autoimmune origin, but the etiology of irritable bowel syndrome remains elusive. Furthermore, classifying patients into irritable bowel syndrome and inflammatory bowel diseases can be difficult without invasive testing and holds important treatment implications. Our aim was to assess the ability of gene expression profiling in blood to differentiate among these subject groups.MethodsTranscript levels of a total of 45 genes in blood were determined by quantitative real-time polymerase chain reaction (RT-PCR). We applied three separate analytic approaches; one utilized a scoring system derived from combinations of ratios of expression levels of two genes and two different support vector machines.ResultsAll methods discriminated different subject cohorts, irritable bowel syndrome from control, inflammatory bowel disease from control, irritable bowel syndrome from inflammatory bowel disease, and ulcerative colitis from Crohn’s disease, with high degrees of sensitivity and specificity.ConclusionsThese results suggest these approaches may provide clinically useful prediction of the presence of these gastro-intestinal diseases and syndromes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Using gene expression data to identify certain gastro-intestinal diseases

Crooke

Tossberg²,

Horst

et al. 2012

J Clin Bioinformatics

View full text Add to dashboard Cite

show abstract

“…As discussed below, diseases such as breast cancer, which were once classified as single diseases, are being stratified into clinically relevant subgroups based on genetic, molecular and cellular network interactions [7]. Other diseases such as prostrate cancer [8] and Crohn’s disease [9] are also being stratified. These stratifications are providing increasingly more accurate diagnoses and cost-effective interventions based on the underlying causes of disease.…”

Section: Systems Approaches To Biology and Disease Are Leading To The Ementioning

confidence: 99%

P4 Medicine: How Systems Medicine Will Transform the Healthcare Sector and Society

Flores

Glusman

Brogaard

et al. 2013

Personalized Medicine

476

331

View full text Add to dashboard Cite

Ten years ago, the proposition that healthcare is evolving from reactive disease care to care that is predictive, preventive, personalized and participatory was regarded as highly speculative. Today, the core elements of that vision are widely accepted and have been articulated in a series of recent reports by the US Institute of Medicine. Systems approaches to biology and medicine are now beginning to provide patients, consumers and physicians with personalized information about each individual’s unique health experience of both health and disease at the molecular, cellular and organ levels. This information will make disease care radically more cost effective by personalizing care to each person’s unique biology and by treating the causes rather than the symptoms of disease. It will also provide the basis for concrete action by consumers to improve their health as they observe the impact of lifestyle decisions. Working together in digitally powered familial and affinity networks, consumers will be able to reduce the incidence of the complex chronic diseases that currently account for 75% of disease-care costs in the USA.

show abstract

“…Although current prognostic markers of CD rely on clinical risk factors such as the need for cortocosteroids, disease onset before the age of 40 years, smoking, the presence of perianal lesions at diagnosis, small bowel localization, and stricturing disease [8,9], these factors are neither sufficient nor accurate [10][11][12][13]. Identification of genetic markers has also been proposed for establishing the prognosis of CD [12].…”

Section: Introductionmentioning

confidence: 99%